Feb 20, 2025 8:30 am EST BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
Dec 5, 2024 6:45 am EST BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Nov 13, 2024 7:00 am EST BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
Nov 12, 2024 4:05 pm EST BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 6, 2024 7:00 am EST BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
Nov 5, 2024 7:10 am EST BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
Oct 31, 2024 7:00 am EDT BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
Oct 10, 2024 7:00 am EDT BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events